Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI3004 |
| Synonyms | |
| Therapy Description |
IBI3004 is a bispecific antibody targeting CEACAM5 and TRAILR2 (DR5), which potentially induces apoptosis in tumor cells expressing CEACAM5 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI3004 | IBI-3004|IBI 3004 | CEACAM5 Antibody 12 | IBI3004 is a bispecific antibody targeting CEACAM5 and TRAILR2 (DR5), which potentially induces apoptosis in tumor cells expressing CEACAM5 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06198426 | Phase Ib/II | IBI3004 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Terminated | AUS | 1 |